Prognostic value of the dynamics of M-type phospholipase A2 receptor antibody titers in patients with idiopathic membranous nephropathy treated with two different immunosuppression regimens

References

• Bech AP, Hofstra JM, Brenchley PE, Wetzels JF. (2014). Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 9:1386–92
   PubMed Web of Science ®Google Scholar
• Beck Jr LH, Bonegio RG, Lambeau G, et al. (2009). M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361:11–21
   PubMed Web of Science ®Google Scholar
• Beck Jr LH, Fervenza FC, Beck DM, et al. (2011). Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 22:1543–50
   PubMed Web of Science ®Google Scholar
• Behnert A, Schiffer M, Müller-Deile J, et al. (2014). Antiphospholipase A2 receptor autoantibodies: a comparison of three different immunoassays for the diagnosis of idiopathic membranous nephropathy. J Immunol Res 143274. doi: 10.1155/2014/143274. Epub 2014 Apr 9. PubMed PMID: 24812637; PubMed Central PMCID: PMC4000632
   Google Scholar
• Caro J, Gutiérrez-Solís E, Rojas-Rivera J, et al.; for the Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN) (2014). Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus. Nephrol Dial Transplant; pii: gfu306 [Epub ahead of print]
   PubMedGoogle Scholar
• Cattran DC, Appel GB, Hebert LA, et al.; North America Nephrotic Syndrome Study Group. (2001). Cyclosporine in patients with steroid resistant membranous nephropathy A randomized trial. Kidney Int 59:1484–90
   PubMed Web of Science ®Google Scholar
• Cattran DC, Greenwood C, Ritchie S, et al. (1995). A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Kidney Int 47:1130–5
   PubMed Web of Science ®Google Scholar
• Donadio Jr JV, Holley KE, Andersons CF, Taylor WF. (1974). Controlled trial of cyclophosphamide in idiopathic membranous nephropathy. Kidney Int 6:431–9
   PubMed Web of Science ®Google Scholar
• Donadio Jr JV, Torres VE, Velosa JA, et al. (1988). Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int 33:708–15
   PubMed Web of Science ®Google Scholar
• Fulladosa X, Praga M, Segarra A, Martínez Ara J. (2007). Tratamiento del síndorme nefrótico primario. Glomerulonefritis membranosa. Nefrología 27:70–86
   Google Scholar
• Hofstra JM, Beck Jr LH, Beck DM, et al. (2011). Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 6:1286–91
   PubMed Web of Science ®Google Scholar
• Hofstra JM, Branten AJ, Wirtz JJ, et al. (2010). Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial. Nephrol Dial Transplant 25:129–36
   PubMed Web of Science ®Google Scholar
• Hofstra JM, Fervenza FC, Wetzels JF. (2013). Treatment of idiopathic membranous nephropathy. Nat Rev Nephrol 9:443–58
   PubMed Web of Science ®Google Scholar
• Hofstra JM, Wetzels JF. (2012). Anti-PLA2R antibodies in membranous nephropathy: ready for routine clinical practice? Neth J Med 70:109–13
   PubMedGoogle Scholar
• Hoxha E, Harendza S, Zahner G, et al. (2011). An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 26:2526–32
   PubMed Web of Science ®Google Scholar
• Hoxha E, Thiele I, Zahner G, et al. (2014). Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol 6:1357–66
   Google Scholar
• Jha V, Ganguli A, Saha TK, et al. (2007). A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 18:1899–904
   PubMed Web of Science ®Google Scholar
• Kanigicherla D, Gummadova J, McKenzie EA, et al. (2013). Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int 83:940–8
   PubMed Web of Science ®Google Scholar
• KDIGO Clinical Practice Guideline for Glomerulonephritis. (2012). Idiopathic membranous nephropathy. Kidney Int Suppl 2:186–97
   Google Scholar
• Kerjaschki D. (2004). Pathomechanisms and molecular basis of membranous glomerulopathy Lancet 364:1194–6
   Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. (2009). CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): a new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–12
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Altieri p. Scolari F, et al. (1998). A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 9:444–50
   PubMed Web of Science ®Google Scholar
• Praga M, Barrio V, Juárez GF, Luño J; Grupo Español de Estudio de la Nefropatía Membranosa. (2007). Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int 71:924–30
   PubMed Web of Science ®Google Scholar
• Qin W, Beck Jr LH, Zeng C, et al. (2011). Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 22:1137–43
   PubMed Web of Science ®Google Scholar
• Segarra-Medrano A, Jatem-Escalante E, Carnicer-Cáceres C, et al. (2014). Evolution of antibody titre against the M-type phospholipase A2 receptor and clinical response in idiopathic membranous nephropathy patients treated with tacrolimus. Nefrologia 4:491–7
   Google Scholar
• van den Brand JA, van Dijk PR, Hofstra JM, Wetzels JF. (2014). Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy. J Am Soc Nephrol 25:150–8
   PubMed Web of Science ®Google Scholar